select trial semaglutide cardiovascular outcomes non-diabetic 2023 align more closely with attained dose than achieved weight loss Effects of semaglutide on risk

The latest on the scene: retatrutide , a so-called "triple-agonist" that targets GLP-1, GIP, and glucagon receptors

Heading into 2026, several states have updated their rules, especially around weight management use

Potential Benefits for Fertility For women with conditions like polycystic ovary syndrome (PCOS), obesity, or insulin resistance, GLP-1 medications may actually improve fertility by: Supporting weight loss Improving insulin sensitivity Helping regulate menstrual cycles These changes can increase the likelihood of ovulation and make conception more achievable

Even with a five-day half-life, the medication remains at a powerful therapeutic level for the full seven days between doses

1, 2021, and Dec

Psychopharmacology 242 , 6370 (2025)